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Abstract: Type 2 diabetes is associated with increased risk for the development of cardiovascular 
disease (CVD) secondary to hyperglycemia’s toxicity to blood vessels. The escalating incidence 
of CVD among patients with type 2 diabetes has prompted research into how lowering glycated 
hemoglobin (HbA1c) may improve CVD-related morbidity and mortality. Data from recent stud-
ies have shown that some patients with type 2 diabetes actually have increased mortality after 
achieving the lowest possible HbA1c using intensive antidiabetes treatment. Multiple factors, 
such as baseline HbA1c, duration of diabetes, pancreatic β-cell decline, presence of overweight/
obesity, and the pharmacologic durability of antidiabetes medications influence diabetes treat-
ment plans and therapeutic results. Hypertension and dyslipidemia are common comorbidities in 
patients with type 2 diabetes, which impact the risk of CVD independently of glycemic control. 
Consideration of all of these risk factors provides the best option for reducing morbidity and 
mortality in patients with type 2 diabetes. Based on the results of recent trials, the appropriate 
use of current antidiabetes therapies can optimize glycemic control, but use of intensive glucose-
lowering therapy will need to be tailored to individual patient needs and risks.
Keywords: type 2 diabetes, diabetes treatment, incretin-based therapies, glucose control, 
HbA1c, cardiovascular disease
Introduction
Diabetes mellitus affects nearly 25 million people in the United States, with more than 90% 
diagnosed with type 2 diabetes.1 Individuals with type 2 diabetes are at risk for a multitude 
of metabolic abnormalities that lead to microvascular and macrovascular complications, 
with cardiovascular disease (CVD) being the leading cause of mortality in these patients.2 
Despite advances in the diagnosis and treatment of CVD, mortality has increased in patients 
with type 2 diabetes at the same time as it has decreased in the general population.3
Because of this alarming trend in patients with type 2 diabetes, reducing CV risk 
factors, including overweight/obesity, elevated blood pressure (BP), and dyslipidemia, 
is just as important as reducing hyperglycemia for maximizing outcomes in this patient 
population.2,4–8 The importance of addressing these issues through individualized patient 
treatment strategies has been confirmed in a number of recent, large-scale clinical trials 
involving patients with type 2 diabetes.9–13
This paper will review data from recently conducted, large-scale clinical trials that 
evaluated the relationship between duration of disease, extent of glucose lowering, 
and cardiometabolic risk/CVD outcomes, and the treatment effects of more recently 
approved antidiabetes agents. The implications of these data on changes in current 
type 2 diabetes treatment practices will also be reviewed.Vascular Health and Risk Management 2010:6 18
Palumbo and Wert Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Optimum intensity of glycemic 
therapy in type 2 diabetes
Although epidemiologic studies indicate an association 
between elevated glycated hemoglobin (HbA1c) and CVD in 
patients with type 2 diabetes, the effects of intensive glucose 
lowering on vascular outcomes remain unclear. Large-scale 
clinical trials enrolling patients with type 2 diabetes, includ-
ing the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) study,9 the Action in Diabetes and Vascular 
Disease: Preterax and Diamicron MR Controlled Evaluation 
(ADVANCE),10 and the Veterans Administration Diabetes 
Trial (VADT),11 were designed to determine whether intensive 
antidiabetes therapy could reduce CVD events in this patient 
population. These studies are summarized in Table 1.
The results from these randomized clinical trials showed 
improved glycemic control (as measured by HbA1c ) with a 
significant difference demonstrated between the intensive 
antidiabetes therapy and the standard therapy groups. Blood 
pressure and serum lipid levels improved with appropriate 
administration of antihypertensive and dyslipidemia treat-
ments with the antidiabetes therapies. While weight gain was 
noted in ACCORD and VADT in the intensive antidiabetes 
therapy group compared with the standard therapy group, 
there was weight loss in both treatment groups in ADVANCE, 
with the greater loss occurring in the standard therapy group 
(−1 kg) versus the intensive therapy group (−0.1 kg). Further, 
ACCORD and ADVANCE were secondary prevention trials 
for CVD in patients with type 2 diabetes and CVD and/or high 
risk for CVD, while the VADT study was a primary prevention 
trial for CVD in veterans with type 2 diabetes.
Data from ACCORD, ADVANCE, and VADT showed 
that reduction of CVD risk factors in patients with type 2 
diabetes is not entirely dependent on the extent of glucose 
lowering. Instead, other factors, including disease duration 
and the presence of CVD comorbidities, have an influence 
on the morbidity and mortality of patients in this popula-
tion. Intensive therapy in ACCORD was discontinued after 
a mean 3.5-year follow-up because of increased mortality in 
this treatment group.9
Disease duration, comorbidities, 
and treatment outcomes in type 2 
diabetes
Vascular complications and disease duration
Studies such as the Diabetes Control and Complications Trial 
(DCCT), the Wisconsin Epidemiologic Study of Diabetic 
Retinopathy (WESDR), and the United Kingdom Prospective 
Diabetes Study (UKPDS) have investigated the influence of 
disease duration and concomitant comorbidities on treatment 
outcomes.
The DCCT evaluated whether intensive antidiabetes 
treatment could decrease the frequency and severity of 
microvascular complications in patients with type 1 diabe-
tes. Data showed that lowering HbA1c was associated with a 
reduced relative risk of microvascular complications, with 
the greatest reductions in patients with HbA1c  9%.14 These 
findings are also important to patients with type 2 diabetes, 
as the pathophysiologic mechanisms driving disease progres-
sion are similar in type 1 and type 2 diabetes. There was no 
significant difference in macrovascular complications (CVD 
or mortality) between the standard and intensive therapy 
groups. However, a majority (93%) of the DCCT participants 
were subsequently followed from 1993–2005 for a mean 
follow-up of 17 years through the Epidemiology of Diabetes 
Interventions and Complications (EDIC) study.15 This study 
concluded that intensive diabetes therapy was independently 
associated with a significant decrease in the risk of CVD after 
the DCCT even though there was no significant difference 
in the HbA1c between the treatment groups in subsequent 
follow-up.
The WESDR examined the 25-year cumulative incidence 
and duration of macular edema (ME) (a commonly encoun-
tered microvascular complication in patients with type 1 
and type 2 diabetes), and its association with various CVD 
risk factors, including hyperglycemia and BP. Data showed 
that elevated HbA1c and systolic BP were associated with an 
increased incidence of diabetic ME (P  0.004 for both) in 
patients with type 1 and type 2 diabetes.16 As the duration 
of diabetes increased, the cumulative incidence of clinically 
significant ME and all-cause mortality also increased.16 
Adjustment of data by patient age and gender showed that 
clinically significant ME was associated with increased CVD 
mortality in patients diagnosed with diabetes when they were 
aged 30 years.17 These data suggest that disease duration 
and the number of diabetes- and CVD-related comorbidities 
increase the morbidity and mortality of patients with type 2 
diabetes.18
Data from other clinical studies have shown that pro-
gression of type 2 diabetes and its related risk factors are 
favorably influenced by early initiation of treatment. In the 
UKPDS, newly diagnosed patients with type 2 diabetes 
(median baseline HbA1c 7.9% to 8.9%) were randomized 
to receive conventional glucose control (diet) or intensive 
glucose control (sulfonylurea [SFU], insulin, or metformin 
[MET]).19 Microvascular risk was reduced between 25% Vascular Health and Risk Management 2010:6 19
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to 29% in the intensive control group compared with the 
conventional control group during the intervention phase of 
the study and remained diminished throughout the 10-year 
post-trial phase despite a convergence of HbA1c in the two 
treatment groups.19 Moreover, although not significant 
during the interventional phase of the trial, patients in the 
SFU-insulin group experienced statistically and clinically 
relevant post-trial reductions in the risk for myocardial 
infarction (MI) (15%, P = 0.01) and all-cause mortality 
(13%, P = 0.007).19
Patients with hypertension in the UKPDS were also ran-
domized to stringent (angiotensin-converting enzyme inhibi-
tor or β-blocker) or less-rigid BP control regimens (without 
these medications).20 During a 6- to 10-year interventional 
phase, mean BP was significantly lowered from baseline 
(146/81 mm Hg) to 143/79 mm Hg in the intensive control 
group compared with a slight increase to 152/82 mm Hg, 
in the less-rigidly controlled group (P  0.001 between 
treatment groups).20 These improvements in BP were asso-
ciated with reduced risk of MI and microvascular disease.20 
Unfortunately, the differences in CVD risk reduction 
between the two treatment groups were not sustained once 
the interventional trial ended.20 These data suggest that 
while early initiation of treating hyperglycemia and vascular 
complications/comorbidities is associated with improved 
morbidity and mortality in patients with type 2 diabetes, 
risk factor controls must be maintained to sustain long-term 
beneficial outcomes.
Other comorbidities and type 2 diabetes
A number of studies (Look AHEAD [Action for Health in 
Diabetes] trial, Framingham Heart study, Diabetes Mellitus 
Insulin Glucose Infusion in Acute Myocardial Infarction 
[DIGAMI] studies, the Bypass Angioplasty Revasculariza-
tion Investigation 2 Diabetes [BARI 2D] trial) have evaluated 
the impact of comorbidities, such as overweight/obesity and 
pre-existing CVD, on the morbidity and mortality of patients 
with type 2 diabetes.
In Look AHEAD, 5145 patients with a body mass index 
(BMI)  25 kg/m2 were treated with either intensive lifestyle 
Table 1 Summary of recent CVD outcome trials in patients with type 2 diabetes9–11,13
ACCORD ADVANCE VADT
Baseline patient characteristics
N 10,251 11,140 1791
Age, mean, y 62 66 60
Duration of type 2 diabetes, y 10.0 8.0 11.5
Patients with CVD history, % 35 32 40
BMi, kg/m2 32 28 31
HbA1c, median, % 8.1 7.2 9.4
Protocol characteristics
Target HbA1c, %  
(intensive vs standard care)
6 vs 7–7.9 6.5 vs usual  
(ie, based on local guidelines)
6 (action if 6.5) vs 
planned separation of 1.5
On-study characteristics
Follow-up, y ∼3.5 (mean) 5.0 (median) 5.6 (median)
Median HbA1c achieved, %  
(intensive vs standard care)
6.4% vs 7.5% 6.3% vs 7.0% 6.9% vs 8.4%
Patients receiving statin therapy, %  
(from baseline to study end)
intensive: 62 → 88 
Standard care: 62 → 88
intensive: 28 → 46 
Standard care: 29 → 48
84 (at study end)a
Patients receiving antiplatelet therapy, %  
(from baseline to study end)
intensive: 55 → 76 
Standard care: 54 → 76
intensive: 49 → 64  
Standard care: 48 → 61
92 (at study end)a
Patients receiving antihypertensive therapy, %   
(from baseline to study end)
intensive: 85 → 91  
Standard care: 86 → 92
intensive: 75 → 89 
Standard care: 75 → 88
72 (at baseline)a
Notes: ain VADT no baseline data was provided for statin or antiplatelet use. The use of statin therapy was 86% in intensively treated and 83% in standard-treated patients 
at study end.   The use of antiplatelet therapy was 94% in intensively treated and 91% in standard-treated patients at study end. 72% of patients in VADT had hypertension by 
study definition at baseline. No data for hypertension/hypertensive therapy at study end was reported.
Abbreviations:  ACCORD,   Action to Control Cardiovascular Risk in Diabetes;   ADVANCe,   Action in Diabetes and Vascular Disease; Preterax and Diamicron MR Controlled 
evaluation; BMi, body mass index; CVD, cardiovascular disease;    VADT,   Veterans   Affairs Diabetes   Trial.Vascular Health and Risk Management 2010:6 20
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intervention (ILI) involving increased physical activity and 
caloric restriction, or diabetes support and education (DSE) 
requiring attendance at support meetings.21 At the end of 
one year, ILI was associated with clinically significant weight 
loss, improved diabetes control, reduced CVD risk factors, 
and a reduction in the use of glucose-lowering medication com-
pared with DSE.21 HbA1c decreased from 7.3% to 6.6% in the 
ILI group and from 7.3% to 7.2% in the DSE group (P  0.001). 
High density lipoprotein-cholesterol (HDL-C) increased from 
baseline (44 mg/dL) in both groups after one year, but was sig-
nificantly more improved in the ILI group (47 mg/dL) compared 
with the DSE group (45 mg/dL, P  0.001).21
CVD is frequently present in overweight/obese patients 
with type 2 diabetes. Individuals with and without obesity 
and diabetes from the original and offspring cohorts of the 
Framingham Heart study were assessed for their lifetime risk 
of CVD.22 Over a 30-year period, the lifetime risk of CVD 
among normal-weight and obese females with diabetes was 
54.8% and 78.8%, respectively.22 Among normal-weight 
and obese males with diabetes, the lifetime risk of CVD was 
78.6% and 86.9%, respectively.22 These data showed that 
the lifetime risk of CVD is higher in patients with type 1 or 
type 2 diabetes and is further accentuated with increasing 
adiposity.
The DIGAMI 1 study established that initial intensive 
metabolic control with intravenous insulin followed by long-
term subcutaneous insulin improved clinical outcomes in 
patients with type 2 diabetes and a prior MI.23 The DIGAMI 2 
study was conducted to determine whether improvement was 
due to initial insulin-glucose infusion or to long-term subcuta-
neous insulin treatment.23 DIGAMI 2 compared three specific 
glucose-lowering regimens in patients with type 2 diabetes 
or elevated blood glucose and a suspected acute MI upon 
hospital admission: 1) a 24-hour insulin-glucose infusion 
followed by long-term subcutaneous insulin; 2) the same ini-
tial infusion treatment followed by standard glucose control; 
and 3) standard glucose control without the initial infusion 
treatment.24 Data demonstrated that although hypoglycemic 
events occurred most often in the first 24 hours after insulin 
treatment (N = 111; 12%) compared with standard glucose 
control, hypoglycemia during time of admission was not 
associated with adverse CV outcomes.25 Only body weight 
(odds ratio [OR], 0.97; 95% confidence interval [CI]: 0.95 
to 0.98; P  0.0001) and diabetes duration (OR, 1.03; 95% 
CI: 1.01 to 1.05; P = 0.0085) were individually predictive of 
hypoglycemia and future morbidity and mortality.25
Upon discharge, patients enrolled in DIGAMI 2 were 
administered various antidiabetes agents, including insulin, 
MET, and SFUs for a median of 2.1 years. The results from 
post-hoc analyses demonstrated that insulin had a greater risk 
(updated, adjusted hazard ratio [HR], 1.73; 95% CI: 1.26 to 
2.37; P = 0.0007) than MET (HR, 0.63; 95% CI: 0.42 to 0.95; 
P = 0.03) and SFU (HR, 0.81; 95% CI: 0.57 to 1.14; P = 0.23) 
for causing nonfatal MI and stroke in patients with type 2 
diabetes.24 Additionally, further subanalysis of DIGAMI 2 
data showed that insulin treatment after MI was associated 
with significantly increased weight gain (+2.3 kg; 95% CI: 1.5 
to 3.2) and a 2.5-times greater incidence of reinfarction.26
Similarly, the BARI 2D trial evaluated whether revas-
cularization and intensive antidiabetes therapy with either 
insulin-sensitization or insulin-provision could improve CV 
outcomes when compared with intensive medical therapy 
alone in patients with type 2 diabetes and stable coronary 
artery disease.27 After five years of treatment, survival rates 
did not differ significantly between revascularization (88.3%) 
and medical therapy (87.8%) groups or between the insulin 
sensitization (88.2%) and insulin provision (87.9%) groups. 
There was also no significant difference in reduction of CV 
events between the revascularization group (77.2%) and 
medical treatment group (75.9%) or between the insulin 
sensitization group (77.7%) and insulin provision group 
(75.4%).28 The results from these trials suggest that multiple 
factors beyond pre-existing conditions, including disease 
and comorbidity duration and intensity of selected therapy, 
interact to affect clinical outcomes in patients with type 2 
diabetes.
Multifactorial intervention
Data from clinical studies have shown that treatment with 
multiple drug combinations can lower the risk of nonfatal CVD 
in some patients with type 2 diabetes. Steno-2 was conducted 
to evaluate the impact of this approach on CV risk factors and 
any-cause and CV-related mortality. Patients (N = 160) with 
type 2 diabetes and persistent microalbuminuria were treated 
with either intensive multifactorial intervention (stringent gly-
cemic regulation, treatment with lipid- and BP-lowering agents, 
and aspirin) or conventional therapy for a mean of 7.8 years and 
followed-up for a mean of 5.5 years.12 Intensive multifactorial 
intervention resulted in significantly lower HbA1c compared 
with conventional therapy (7.9% vs 9.0%; P  0.01), but 
these differences were no longer significant at the end of 
follow-up (7.7% vs 8.0%).12 After intervention, mean BP was 
reduced significantly with intensive (131/73 mm Hg) therapy 
compared with conventional (146/78 mm Hg) therapy, from 
146/85 mm Hg and 149/86 mm Hg, respectively (P  0.01 
between treatment groups); significance was not maintained Vascular Health and Risk Management 2010:6 21
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during the follow-up period. Fasting serum cholesterol was 
also significantly reduced with intensive (159 mg/dL) therapy 
compared with conventional (216 mg/dL) therapy, from 
210 mg/dL and 233 mg/dL, respectively (P  0.01 between 
treatment groups); again, significant improvements were not 
maintained after follow-up.12
Steno-2 data also showed that intensive multifactorial 
therapy was associated with sustained and beneficial effects 
on vascular complications, and any-cause, and CVD-related 
mortality. Nine patients in the intensive therapy group died 
from CVD-related causes compared with 19 in the conventional 
therapy group (P = 0.03).12 Diabetic nephropathy, progression 
of diabetic retinopathy, and autonomic neuropathy were sig-
nificantly improved in the intensive therapy group compared 
with the conventional therapy group over the 13.3 years of 
observation (P  0.01 for all).12 Although these data indicate 
that multifactorial care for patients with type 2 diabetes lowers 
CVD risk factors, morbidity, and mortality, the prompt and 
intensive implementation of antidiabetes treatments remains 
a formidable challenge in this patient population.
Treatment strategies for type 2 
diabetes
Guidelines for the treatment of type 2 diabetes have been 
developed by various professional societies, including the 
American Association of Clinical Endocrinologists (AACE) 
and the American Diabetes Association (ADA). The guide-
lines, which are summarized in Table 2, provide target goals 
for several factors including glucose, BP, and lipids.2,5 Clini-
cians are encouraged to consider the individual patient needs 
and to encourage lifestyle changes. Results from clinical 
studies indicate that these targets are generally reasonable and 
obtainable but should be individualized and tailored to the needs 
and abilities of the patient with type 2 diabetes. Adjustments 
may be necessary for patients aged 65 years or older with and 
without comorbidities and for other individuals with mental 
and physical health challenges in order to avoid the potential 
hazards associated with tight glycemic control.
A list of selected antidiabetes pharmacotherapies with 
their advantages and disadvantages are presented in Table 3. 
Many of the available medications, including insulin, SFUs, 
thiazolidinediones (TZDs), and glinides, are associated with 
weight gain.8 MET, α-glucosidase inhibitors, and dipeptidyl 
peptidase-IV (DPP-IV) inhibitors are considered weight-
neutral,8 while the glucagon-like peptide-1 (GLP-1) receptor 
agonists, amylin, and amylin analogs, are associated with 
weight loss.8 Insulin therapy may be useful in the under-
nourished patient to improve nutritional status and weight 
while avoiding hypoglycemia. Several reviews discuss the 
mechanisms of action and impact of these medications on 
other CVD comorbidities.8,29,30
The ADA and the European Association for the Study of 
Diabetes has developed a consensus algorithm to help guide 
initiation and adjustment of diabetes therapy using these 
agents (Figure 1).8 In addition to lifestyle improvements, this 
algorithm recognizes that clinicians have several antidiabe-
tes medications available to help achieve glycemic targets. 
MET, SFU, and insulin are considered tier 1 core therapies, 
while tier 2 therapies include pioglitazone and a GLP-1 
receptor agonist.8 Rosiglitazone is not recommended for use, 
and DPP-IV inhibitors are not listed. If tier 1 medications 
do not offer optimal benefits/glucose lowering, the use of 
additional agents, such as pioglitazone or a GLP-1 receptor 
agonist from tier 2, may be considered to provide glycemic 
Table 2 Comparison of guidelines for the management of patients with type 2 diabetes
Target treatment goals AACE/ACE (2007)5 ADA (2009)2
HbA1c 6.5% 7%
Fasting glucose Fasting plasma glucose 110 mg/dL Preprandial capillary plasma 
glucose, 70–130 mg/dL
Postprandial glucose 2-hr postprandial glucose 140 mg/dL Peak postprandial capillary 
plasma glucose 180 mg/dL
BP 130/80 mm Hg 130/80 mm Hg
Lipids LDL-C 100 mg/dL (70 mg/dL for patients 
with diabetes and coronary artery disease)  
HDL-C 40 mg/dL in men, 50 mg/dL in 
women  
Triglycerides 150 mg/dL
LDL-C 100 mg/dLa  
 
HDL-C 50 mg/dL  
 
Triglycerides 150 mg/dL
Notes: ain individuals with overt CVD, a lower LDL-C goal of 70 mg/dL (1.8 mmol/L), using high doses of a statin, is an option.
Abbreviations: AACe,   American Association of Clinical endocrinologists;   ACe, American College of endocrinology;   ADA,   American Diabetes Association; BP, blood pressure; 
CVD, cardiovascular disease; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol.Vascular Health and Risk Management 2010:6 22
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benefit. GLP-1 receptor agonists have the added benefit of 
promoting weight loss.8
The International Diabetes Center algorithm also includes 
goals and options for glycemic treatment.7 Beginning with 
complete lifestyle management, this algorithm recommends 
commencing treatment with MET and advancing to a two-
drug therapy if target glycemic goals are not achieved within 
three months. The algorithm also includes guidance on the 
effect of antidiabetes therapy on hypoglycemia and weight 
(ie, among two drug therapies, only one promotes weight loss; 
the combination of MET and GLP-1 receptor agonist).7
A pathophysiology-based algorithm has been recently 
presented as an alternative to the ADA guidelines for the 
treatment of type 2 diabetes.6 This algorithm is based on 
targeting the pathophysiologic defects associated with diabe-
tes, including impaired insulin secretion, increased lipolysis, 
decreased glucose uptake, and increased hepatic glucose 
production.6 Through lifestyle changes and triple therapy 
with a TZD, MET, and the GLP-1 receptor agonist exenatide, 
the regimen durably lowers hyperglycemia without inducing 
weight gain.6 Early commencement with this antidiabetes 
regimen should help to delay/prevent the progressive β-cell 
failure experienced by patients with type 2 diabetes.6
Newer therapies for type 2 diabetes
Amylin agonist
Patients with type 2 diabetes are deficient in the neuroendo-
crine hormone amylin, which is secreted by pancreatic β-cells 
(along with insulin) in response to nutrient intake.31 Amylin 
suppresses postprandial glucagon secretion and regulates 
gastric emptying and appetite.31 Treatment with pramlintide, 
a synthetic amylin agonist, as adjunctive therapy to insulin 
with or without oral antidiabetes agents, has been associated 
with improvements in glycemic control (up to –0.7% reduc-
tion in HbA1c), weight (up to –1.6 kg), and selected markers 
of CV risk (postprandial excursions of glucose, nitrotyrosine, 
and oxidized low-density lipoprotein-cholesterol [LDL-C]), 
without increased risk of hypoglycemia in patients with 
type 2 diabetes.32–34
GLP-1 receptor agonists
Incretins are gastrointestinal hormones that stimulate insu-
lin release from pancreatic β-cells. The “incretin effect” 
describes the increased insulin secretion resulting from oral 
compared with intravenous glucose administration.35 It has 
been estimated that the incretin effect represents between 
30% and 60% of the peripheral venous insulin response.35 
As this represents a considerable proportion of postprandial 
insulin release, interest in developing incretins as diabetes 
treatment has increased over the past several years.
GLP-1 is a potent incretin hormone that is rapidly secreted 
by gut cells following a meal,36 although the enzyme DPP-IV 
rapidly metabolizes GLP-1 to an inactive fragment.37 Thus, 
the GLP-1 signaling pathway has been leveraged as a focus 
for diabetes research in two ways. First, GLP-1 receptor 
agonists have been developed that are resistant to DPP-IV 
Table 3 effects on HbA1c, advantages and disadvantages of oral and parenteral antidiabetes agents13
Intervention Advantages Disadvantages
Sulfonylureas Rapidly effective Weight gain, hypoglycemia (especially with glyburide 
[dibenclamide in the eU] and chlorpropamide)
Metformin Weight neutral Gi side effects, contraindicated in patients with renal 
insufficiency
TZDs Improved lipid profile (pioglitazone), 
potential decrease in MI (pioglitazone)
Weight gain, fluid retention, CHF, bone fractures, 
expensive, potential increase in MI (rosiglitazone)
α-Glucosidase inhibitors Weight neutral Frequent Gi side effects, TiD dosing
Glinides (meglitinides) Rapidly effective Weight gain, TiD dosing, hypoglycemia
DPP-iV inhibitors Weight neutral Risk of pancreatitis, renal failure
insulin No dose limit, rapidly effective, 
improved lipid profile
Weight gain, multiple daily injections, monitoring, 
hypoglycemia
GLP-1 receptor agonist Weight loss Frequent Gi side effects, risk of pancreatitis, renal 
failure
Amylin/amylin analogue 
(pramlintide)
Weight loss Frequent Gi side effects, TiD dosing, long-term 
safety not established
Abbreviations: CHF, congestive heart failure; DPP-iV, dipeptidyl peptidase-iV; eU, european Union; Gi, gastrointestinal; GLP-1, glucagon-like peptide-1; Mi, myocardial infarction; 
TZDs, thiazolidinediones.Vascular Health and Risk Management 2010:6 23
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degradation, and second, small molecules that inhibit DPP-IV 
activity have been developed.37
Exenatide, the synthetic form of exendin-4, which 
is 53% homologous to human GLP-1, binds the GLP-1 
receptor agonist on pancreatic β-cells to potentiate insulin 
secretion.8,38 Exenatide has been approved by the US Food 
and Drug Administration (FDA) for use as an adjunctive 
therapy to improve glycemic control in patients with type 2 
diabetes.8 Exenatide was shown to improve glucose levels 
and a number of CVD risk factors, including body weight, 
triglycerides (TG), total cholesterol, HDL-C, LDL-C, systolic 
BP (SBP) and diastolic BP in patients with type 2 diabetes 
treated for 3 years.39 In patients with type 2 diabetes previ-
ously treated with MET, the addition of exenatide improved 
hyperglycemic clamp-derived measures of β-cell function 
more than insulin glargine (P  0.0001).40 In addition, in 
a retrospective database study, treatment with exenatide 
was associated with significant reduction in mean body 
weight (−2.7 kg; P  0.001), BMI (−0.9 kg/m2; P  0.001), 
abdominal girth (−2.9 cm; P  0.001), total cholesterol 
(−7.4 mg/dL; P  0.001), TG (−16.7 mg/dL; P  0.001), 
and BP (–2.6/–1.2 mm Hg; P  0.03).41
In pooled datasets from two studies, the addition of exena-
tide to patients treated with MET and an SFU for six months 
resulted in more patients reaching an HbA1c  6.5% with 
significantly greater reductions in body weight (up to 
−3.7 kg; P  0.0001) and SBP (−7.2 mm Hg; P  0.005) 
than in patients who received insulin glargine or biphasic 
insulin aspart.42 In two other studies, exenatide produced 
greater reductions in SBP than either biphasic insulin aspart 
(−4.9 mm Hg vs −0.5 mm Hg; P  0.0001) or placebo 
(−1.7 mm Hg vs +0.4 mm Hg; P  0.0005).43
A long-acting, once-weekly formulation of exenatide 
(which lowers glucose via the same mechanism as the 
Tier 1:  Well-validated core therapies Tier 2:  Less well-validated therapies
STEP 1
STEP 2
STEP 3
At diagnosis:
Lifestyle
Lifestyle + Metformin Lifestyle + Metformin
Lifestyle + Metformin Lifestyle + Metformin
Lifestyle + Metformin Lifestyle + Metformin
Lifestyle + Metformin
+
+ +
+
+
+
+
+
+
Metformin
Sulfonylureaa
Sulfonylureaa
Basal insulin
Basal insulin
Intensive insulin
Pioglitazone
Pioglitazone
GLP-1b agonist
No hypoglycermia
Weight gain
Edema/CHF
Bone loss
No hypoglycemia
Weight loss
Nausea/vomiting
Figure 1 ADA/eASD consensus guidelines treatment algorithm for patients with type 2 diabetes. Reinforce lifestyle interventions at every visit; check HbA1c every three months 
until HbA1c is 7% and then at least every six months.   The interventions should be changed if HbA1c is 7%. Copyright © 2009.   Adapted with permission from Nathan DM, 
Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement 
of the American Diabetes Association and the european Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203.
Notes: aSulfonylureas other than glyburide or chlorpropamide. bInsufficient clinical use to be confident regarding safety.
Abbreviations: ADA, American Diabetes Association; CHF, congestive heart failure; eASD, european Association for the Study of Diabetes; GLP-1, glucagon-like peptide-1.Vascular Health and Risk Management 2010:6 24
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approved BID formulation) is currently under regulatory 
review by the US FDA.36,44 A 30-week, noninferiority trial in 
patients with type 2 diabetes receiving MET, a SFU, a TZD, 
or a combination of two of these agents, was conducted to 
compare exenatide administered twice daily to once weekly.44 
Both treatment groups had reductions in HbA1c by week 6. 
Beginning at week 10 and continuing through the remainder 
of the trial, exenatide once weekly was associated with 
greater reductions in HbA1c than twice-daily dosing.44 After 
30 weeks, the mean HbA1c reduction was −1.9% for exenatide 
once weekly versus −1.5% for twice daily (P = 0.002).44 
Weight loss was similar (−3.7 kg) with both treatment 
regimens.44 Incidence of transient treatment-related nausea 
was significantly greater in the twice-daily group (34%; 
50/145) compared with the once-weekly group (26.4%; 
39/148; P  0.05), while transient injection site pruritus was 
more commonly reported in the once-weekly group (17.6%; 
26/148 vs 1.4%; 2/145). These events subsided over the 
duration of the study.44
Liraglutide, an injectable GLP-1 receptor agonist with 
97% homology to human GLP-1 and partial resistance to 
DPP-IV (through amino acid substitution and palmitate 
side chain addition), is being investigated in a once-daily 
formulation, and has recently been approved for use in the 
European Union.36 In the 26-week Liraglutide Effect and 
Action in Diabetes (LEAD)-2 MET study, patients with 
type 2 diabetes on a stable regimen of MET were treated 
with liraglutide, glimepiride, or placebo.45 After 12 weeks 
of therapy, liraglutide and glimepiride were associated with 
greater reductions in HbA1c (−0.7% to −1.0%) than placebo 
(−0.09%; P  0.0001).45 Liraglutide reduced body weight 
up to −2.8 kg compared with a +1 kg weight gain with 
glimepiride (P  0.0001).45 Liraglutide was associated with 
a greater incidence of nausea, vomiting, and diarrhea than 
either glimepiride or placebo, although the events were tran-
sient and subsided over the course of the study.45
In a 52-week study, patients with type 2 diabetes receiv-
ing liraglutide monotherapy had significantly greater reduc-
tions from baseline HbA1c (∼8.3%) than patients receiving 
glimepiride monotherapy (−1.1% vs −0.5%; P  0.001).46 
Unlike glimepiride, treatment with liraglutide was associated 
with weight loss (approximately −2.3 kg) while patients on 
glimepiride gained approximately 1 kg (P = 0.0001).46
DPP-iV inhibitors
Sitagliptin, an oral antidiabetes agent, has been shown to 
inhibit plasma DPP-IV activity by ∼90% after two hours and 
by ∼80% after 24 hours post-dose.47 Sitagliptin monotherapy 
was associated with significant (P  0.001) improvement in 
HbA1c (up to −0.9%) in a 24-week study of patients with a 
mean 4.4-year duration of type 2 diabetes.48
Sitagliptin has also been studied in type 2 diabetes 
patients with inadequate glycemic control on MET alone.49 
After 26 weeks of therapy, sitagliptin was well tolerated 
and provided significant improvement in HbA1c compared 
with placebo (−0.7% vs −0.02%; P  0.001).49 In patients 
receiving inadequate glycemic control on pioglitazone, 
sitagliptin provided significant decreases (–0.9%) from 
baseline HbA1c (∼8.1%) compared with placebo (−0.2%; 
P  0.001).50
Saxagliptin, another DPP-IV inhibitor, was recently 
approved for use in type 2 diabetes by the US FDA. In clinical 
studies, saxagliptin has been demonstrated to be effective 
in glucose-lowering in patients with type 2 diabetes either 
as monotherapy51 or in combination with other agents 
(eg, MET, SFU).52,53
Implications of treatment decisions 
on the reduction of CVD risk
Based on data from multiple clinical trials, the current HbA1c 
goals for patients with type 2 diabetes appear appropriate. 
However, HbA1c values lower than 6.5% to 7% may not 
provide any clinical advantages in certain patient popula-
tions and may, in fact, increase mortality in patients with an 
already elevated risk for CVD. Although weight loss may be 
difficult for some patients with type 2 diabetes to achieve, 
it is associated with improvements in CVD- and diabetes-
related risks.21 Additionally, longer duration of type 2 diabe-
tes is associated with poorer clinical outcomes.9,13 Because 
patients with type 2 diabetes commonly present with varying 
levels of these risks, it is important to customize antidiabetes 
treatments within the framework of recommended treatment 
guidelines. Evidence continues to accumulate in support of 
newer antidiabetes agents, such as incretin-based therapies 
(GLP-1 receptor agonists and DPP-IV inhibitors), which 
improve hyperglycemia and other CVD risk factors/markers 
(eg, weight, BP, lipids). These incretin-based therapies 
address an additional hormone deficiency present in patients 
with type 2 diabetes and expand the options for optimizing 
glucose control and management of the disease. However, 
undue delay in initiating insulin therapy with deteriorating 
glycemic control in order to try a variety of new noninsulin 
therapies should be avoided. Earlier initiation of insulin 
treatment should be considered to correct rising glycemia, 
particularly in patients with type 2 diabetes of more than 
10 years duration.Vascular Health and Risk Management 2010:6 25
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Conclusions
Patients with type 2 diabetes have an elevated risk of CVD 
secondary to their hyperglycemia. This risk is compounded by 
the presence of common comorbidities including overweight/
obesity, hypertension, and dyslipidemia. Addressing these 
risks simultaneously has beneficial effects on treatment out-
comes. Some of the current antidiabetes pharmacotherapies, 
such as MET, α-glucosidase inhibitors, and incretin-based 
therapies have beneficial effects on hyperglycemia and other 
surrogate markers of CVD risk without increasing weight. 
SFUs, TZDs, glinides, and insulin control glycemia and 
reduce CV risk factors but are associated with weight gain.
The duration of diabetes has an independent and nega-
tive impact on CVD risk and is related to the progression of 
morbidity and mortality. As evidenced by the results from 
recent, large-scale clinical trials, HbA1c target goals do not 
need to be drastically revised for patients with type 2 diabetes. 
Prompt initiation of antidiabetes treatment and individualized 
clinical judgment for each patient is paramount in treating 
hyperglycemia and its comorbidities. Earlier initiation of 
insulin therapy to optimize glycemic control should be con-
sidered in the management of type 2 diabetes.
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